Podcasts about dermavant sciences

Plaque psoriasis is a lifelong disease with no cure, but living well with clearer skin is possible. This World Psoriasis Day dermatologist/rheumatologist Dr. Alice Gottlieb discusses the benefits of a once-daily, steroid-free prescription treatment for adults with plaque psoriasis. Discover how this effective, safe and well-tolerated option can help manage plaque psoriasis, even on affected sensitive areas. This episode is sponsored by Dermavant Sciences. 

Media star spreads hope - Jane's special guest today is global beauty and Internet lifestyle influencer Michelle Lee. Michelle reaches more than 40,000 followers each day with her content and comments about skincare, fashion, and beauty, as she chronicles her adventures to her loyal, world-wide audience. In fact, she comes on the show hot off the plane following a dash to Bora Bora where she swam with sharks!  But this glittering, globe-trotting life is the glamorous side of a serious condition. When Michelle is not sharing fashion tips, she's busy advocating for those with skin issues, namely plaque psoriasis, from which she also suffers. Indeed, she gives hope for the 8 million people in the US impacted by this autoimmune disease and for the millions more around the world who experience visible side effects that impact their overall well-being. Along with hearing Michelle's story of her personal struggle, and particularly her ability to overcome them, on this segment, she and Jane also talk about her almost being a reality TV star, what it's like to have an identical twin, and even how she found true love!  Her tips and tools for diet, exercise and combating stress complement her advice for treatment options for psoriasis. To that end, she has partnered with biopharmaceutical giant, Dermavant Sciences, to spread the word. All in all, Michelle's message is the best way for all of us to become Better Than Before, physically, mentally and spiritually. 

Welcome to the Med Spa Success Strategies Podcast, presented by Ricky Shockley of Med Spa Magic Marketing. On this episode, we're joined by Dr. Brandon Kirsch of Kirsch Dermatology & Med Spa to discuss lessons learned, strategies, and tactics that allowed him to build a highly successful and reputable practice in Naples, FL. Kirsch Dermatology is known for excellence in patient care as evidenced by their incredible online reviews. Dr. Kirsch shares how he went from the "new-in-town" to a highly sought-after provider with the help of online marketing and an emphasis on providing top-tier patient experience. He also shares important lessons he learned along the way about financial planning, a profit-first mindset, and more. Per usual, I'm confident you'll get more than a few tidbits from this interview that, if put to use, will shape your practice for the better. If you're ready to implement more efficient & effective marketing strategies for your practice, book your FREE strategy session & marketing plan: https://go.medspamagicmarketing.com/schedule About Dr. Brandon Kirsch - Kirsch Dermatology & Med Spa Dr. Brandon Kirsch's work spans the worlds of dermatology, technology, business and law. He is a board-certified dermatologist who started his career as a lawyer and holds law degrees from the University of Western Ontario (LL.B.) and Georgetown University (LL.M. Securities and Financial Regulation). He completed medical school at Brown University, an internship at the Mayo Clinic and dermatology residency at the University of North Carolina. Dr. Kirsch serves as Chief of Dermatology for Naples Community Hospital. He has previously worked as Assistant Clinical Professor of Dermatology at the University of Colorado, Vice President and Therapeutic Area Head of Dermatology at the global biopharmaceutical company Arena Pharmaceuticals, and Vice President and Medical Director at Brickell Biotech, Inc. In his roles at Arena and Brickell, he was responsible for providing leadership and strategic direction to the clinical science team and overseeing research studies. Dr. Kirsch has also provided strategic medical consulting for the clinical-stage biopharmaceutical company Dermavant Sciences, Inc. Dr. Kirsch is a frequent contributor to the HuffPost and has been published in the Journal of the American Medical Association, Journal of the American Academy of Dermatology, Journal of Drugs in Dermatology, Journal of Clinical and Aesthetic Dermatology, Dermatology Times, The Journal of Investigative Dermatology, The Journal of Cancer Immunology Research, The Canadian Journal of Neurological Sciences, Reason, The Wall Street Journal, The Toronto Star, The Providence Journal, and The Jacksonville Times-Union. Read more about Dr. Kirsch's story here: https://www.kirschderm.com/dr-brandon-kirsch/ Read more about Kirsch Dermatology here: https://www.kirschderm.com/why-choose-us/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/MPM865. CME/MOC/NCPD/AAPA credit will be available until February 6, 2025.Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerErin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.Co-Chair/PlannerDavid Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/MPM865. CME/MOC/NCPD/AAPA credit will be available until February 6, 2025.Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerErin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.Co-Chair/PlannerDavid Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Faculty/PlannerLakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Faculty/PlannerLakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Faculty/PlannerLakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Faculty/PlannerLakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Faculty/PlannerLakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Faculty/PlannerLakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

In this episode, dermatologists Dr. April Armstrong and Dr. James Song discuss the impact of psoriasis on a patient's quality of life and how steroid-free prescription topical medications can meet the treatment needs of adults with plaque psoriasis. This Psound Bytes episode is sponsored by Dermavant Sciences. 

In part 2 with Stacy Williams, Vice President of Marketing for Dermavant Sciences, Dr. Kamangar and Stacy chat about the role of women in dermatology and the future they're building for the next generation of dermatologists.

In part I of 2, Dr. Kamangar chats with Stacy Williams, Vice President of Marketing for Dermavant Sciences about empowering patients and caregivers to ask the questions and advocate for yourself when it comes to your prescriptions.

Psoriasis is a lifelong disease with no cure, but that doesn't mean you can't thrive in your everyday life. Listen as board-certified dermatologist Dr. Mona Shahriari, shares tips to overcome plaque psoriasis and maintain a high quality of life. This Psound Bytes™ episode is sponsored by Dermavant Sciences. For Important Safety and Prescribing Information visit VTAMA.com. 

Last week, the US Food and Drug Administration approved tapinarof cream, 1% (VTAMA) for the treatment of plaque psoriasis of all severities in adult patients, ushering in the first and only FDA-approved steroid-free topical medication in its class. Remarkably, it had been 25 years since a novel chemical entity had been introduced into psoriasis care from a brand-new mechanism of action, and from the data gathered from the phase 3 PSOARING 1 and 2 trials as well as the long term extension (LTE) study, it couldn't have come at a better time. Pivotal phase 3 data showed treatment with tapinarof cream led to statistically significant improvements in Physician Global Assessment (PGA) score of “clear” or “almost clear” with a minimum 2-grade improvement compared with vehicle treatment from baseline to week 12. Better yet, the median duration of clear or almost clear skin was approximately 4 months after cessation of treatment with tapinarof cream, which was detailed in the phase 3 LTE study for patients who achieved clear skin (PGA 0) during PSOARING 1 or 2. “I think the patients that participated and had exposure to the product for up to a year, were indicating that to us that (tapinarof cream) was easy to use, it was extremely well tolerated, it had remarkable impact on their disease, and the fact that they can discontinue therapy for an extended period of time is absolutely incredible,” said Philip Brown, MD, JD, Chief Medical Officer at Dermavant Sciences. For this episode of DocTalk, Brown and Chief Executive Officer Todd Zavodnick joined the program to speak to the implications of the FDA decision, and how tapinarof cream is set to revolutionize psoriasis management.

This week on Pharm5: Rare monkeypox spreading globally Metformin not helpful in breast cancer survival Novel, nonsteroidal Vtama (tapinarof) for plaque psoriasis Short-course antibiotics for P. aeruginosa bacteremia COVID-19 vaccine saves lives and money References: LaMotte S. What is monkeypox, its symptoms and threat to you? CNN. https://www.cnn.com/2022/05/24/health/what-is-monkeypox-virus-explainer-update-wellness/index.html. Published May 26, 2022. Accessed May 26, 2022. Goodwin PJ, Chen BE, Gelmon KA, et al. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients with Breast Cancer. Journal of the American Medical Association. 2022;327(20):1963-1973. doi:10.1001/jama.2022.6147. Kansteiner F. Dermavant looks to dethrone topical steroids with first FDA approval for Vtama in psoriasis. Fierce Pharma. https://www.fiercepharma.com/pharma/dermavant-looks-dethrone-topical-steroids-first-ever-fda-approval-vtama-psoriasis. Published May 24, 2022. Accessed May 26, 2022. Dermavant Sciences. Dermavant FDA Approves Dermavants VTAMA tapinarof cream 1 for the Treatment of Plaque Psoriasis in Adults First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Years Comments. https://www.dermavant.com/u-s-fda-approves-our-novel-topical-treatment-for-adults-with-plaque-psoriasis/. Accessed May 26, 2022. Babich T, Naucler P, Valik JK, et al. Duration of treatment for pseudomonas aeruginosa bacteremia: A retrospective study. Infectious Diseases and Therapy. 2022. doi:10.1007/s40121-022-00657-1 Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the pfizer-biontech COVID-19 vaccine (BNT162B2) in the first year of rollout in the United States. Journal of Medical Economics. 2022;25(1):605-617. doi:10.1080/13696998.2022.2071427.

Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance. He served in global leadership roles at ZELTIQ Aesthetics prior to the company's acquisition by Allergan; at Galderma Laboratories, where he was President and General Manager of North America; and at Alcon Laboratories. He is a member of the board of directors of the Children's Skin Disease Foundation. On August 10, 2021, after this interview was recorded, Dermavant Sciences announced that the FDA accepted for filing a New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.